NAMS earnings date and last-quarter result: last quarter beat, P/E -17.51. Updated 2026-07-23.
NewAmsterdam Pharma (NAMS) Research Hub
NewAmsterdam Pharma (NAMS) trades on NASDAQ, NL in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 19.53 USD (-0.91%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -17.51, market cap 3.70B. This hub links to the full technical, earnings and options research available for NAMS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, NL |
| Last close | 19.53 USD (-0.91%) |
| 52-week range | 19.13 USD – 37.37 USD |
| Trend regime | Range |
| 14-day RSI | 33.1 (Bearish) |
| Trailing P/E | -17.51 |
| Market cap | 3.70B |
| Dividend yield | 0.00% |
Available research for NAMS
Covered Call on NAMS: how it works, illustrative setup around the real 19.53 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NAMS: how it works, illustrative setup around the real 19.53 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NAMS: how it works, illustrative setup around the real 19.53 USD price, max profit/loss, breakeven and when to use it. Educational.
NAMS technical analysis: range, last 19.53 USD, RSI 33.1, 52w range 19.13 USD–37.37 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is NAMS in?
NewAmsterdam Pharma (NAMS) is classified under Healthcare (Biotechnology), listed on NASDAQ, NL.
Is NAMS in an uptrend or downtrend?
As of 2026-10-26, NAMS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NAMS's trailing P/E ratio?
NAMS's trailing P/E is -17.51, with a market cap of 3.70B. See the earnings research page for full valuation detail.